Dexcel Pharma Technologies Ltd. FDA Approval NDA 214278

NDA 214278

Dexcel Pharma Technologies Ltd.

FDA Drug Application

Application #214278

Documents

Letter2020-10-21

Application Sponsors

NDA 214278Dexcel Pharma Technologies Ltd.

Marketing Status

Prescription001

Application Products

001TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL20MG0ESOMEPRAZOLEESOMEPRAZOLE

FDA Submissions

TYPE 3; Type 3 - New Dosage FormORIG1AP2020-10-20STANDARD

Submissions Property Types

ORIG1Null15

CDER Filings

Dexcel Pharma Technologies Ltd.
cder:Array
(
    [0] => Array
        (
            [ApplNo] => 214278
            [companyName] => Dexcel Pharma Technologies Ltd.
            [docInserts] => ["",""]
            [products] => [{"drugName":"ESOMEPRAZOLE","activeIngredients":"ESOMEPRAZOLE","strength":"20MG","dosageForm":"TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL","marketingStatus":"Prescription","te":"None","rld":"No","rs":"No"}]
            [labels] => 
            [originalApprovals] => [{"actionDate":"10\/20\/2020","submission":"ORIG-1","actionType":"Approval","submissionClassification":"Type 3 - New Dosage Form","reviewPriority":"STANDARD","inserts":"[{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2020\\\/214278Orig1s000ltr.pdf\"}]","notes":"> Label is not available on this site."}]
            [supplements] => 
            [actionDate] => 2020-10-20
        )

)

© 2020 FDA.report
This site is not affiliated with or endorsed by the FDA.